SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 7, 2002
Indevus Pharmaceuticals, Inc.
-----------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-18728 04-3047911
--------------------------------------------------------------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
One Ledgemont Center
99 Hayden Avenue
Lexington, Ma 02421-7966
----------------------------------------
(Address of principal executive offices)
Registrant's telephone number, including area code:
(781-861-8444)
Interneuron Pharmaceuticals, Inc.
---------------------------------
(Former Name)
ITEM 5. Other Events and Regulation FD Disclosure.
On June 7, 2001, Indevus Pharmaceuticals, Inc., formerly known as
Interneuron Pharmaceuticals, Inc. (the "Company"), issued a press release
containing the information attached hereto as Exhibit 99.1 announcing that
Pfizer Inc. ("Pfizer") will return to the Company exclusive, worldwide
development and commercialization rights to pagoclone, a drug in advanced
clinical stage testing to treat anxiety disorders. Pfizer also informed the
Company that the results of its most recent clinical trials with pagoclone in
generalized anxiety disorder and panic disorder did not achieve the level of
efficacy established in previous trials and accordingly, Pfizer has elected not
to pursue further development of pagoclone. The press release is incorporated
herein by reference.
The exhibit hereto contains forward-looking statements that involve risks
and uncertainties that could cause our actual results and financial condition to
differ materially from those anticipated by the forward-looking statements. The
words "believe", "expect", "anticipate", "intend", "plan", "estimate" or other
expressions which are predictions of or indicate future events and trends do not
relate to historical matters but identify forward-looking statements. Risks and
uncertainties related to forward-looking statements are set forth in the
Company's filings under the Securities Act of 1933 and the Securities Exchange
Act of 1934 under "Risk Factors" and elsewhere in, or incorporated by reference
into, the Company's Form 10-K for its fiscal year ended September 30, 2001 and
elsewhere.
Item 7. Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired: N/A
(b) Pro Forma Financial Information: N/A
(c) Exhibits:
Exhibit No. Description of Exhibit
----------- ----------------------
Exhibit 99.1 Press Release dated June 7, 2002
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INTERNEURON PHARMACEUTICALS, INC.
Dated: June 7, 2002 By: /s/ Glenn L. Cooper, M.D.
------------------------------
Glenn L. Cooper, M.D.
President, Chief Executive
Officer and Chairman
-3-